Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alector Inc.
Eisai is testing its anti-tau antibody in combination with the anti-amyloid therapy Leqembi, and earlier-stage programs targeting TrkA, EphA4 and TREM2 offer new approaches and combo potential.
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
Private Company Edition: Patient Square’s private equity fund, which surpassed its $3bn fundraising goal, may invest broadly across health care but the firm already has invested heavily in biopharma. Also, investor Dimension launches with a $350m specialized VC fund and Alto increased its series B to $60m.
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Alector LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.